Integra LifeSciences Holdings Corporation (IART) Soars to 52-Week High, Time to Cash Out?
Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
IART - Integra LifeSciences Holdings Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$21.00
DETAILS
HIGH:
$25.00
LOW:
$19.00
MEDIAN:
$19.00
CONSENSUS:
$21.00
UPSIDE:
9.09%
Stock News
Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open.
IART Stock Surges 52.1% in a Year: What's Driving the Rally?
Integra LifeSciences has climbed 52.1% in a year as growth across both segments, improved execution and transformation efforts continue to boost results.
Here's Why Integra LifeSciences (IART) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Integra (IART) Is Attractively Priced Despite Fast-paced Momentum
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Integra (IART) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
IART or SONVY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
Kirlew will lead Integra's global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution. Kirlew will lead Integra's global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution.
Integra Lifesciences Holdings Corp (IART) Shares Fall 4.2% -- What GF Score of 71 Tells Investors
On June 30, 2026, Integra Lifesciences Holdings Corp (IART) shares fell 4.2% to $17.98, amid a 52-week trading range of $8.70 to $18.92. This decline comes desp
Bet on These 3 Stocks as Broker Rating Upgrades Signal Upside
MITT, SVM and IART stand out as broker rating upgrades, earnings growth forecasts and screen criteria point to potential upside.
Integra LifeSciences Announces Key Executive Appointments
PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Corporation Holdings (Nasdaq: IART), a global leader in medical technology, today announced several leadership appointments within its commercial organization.
Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integra (IART) Shows Fast-paced Momentum But Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Integra (IART) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Integra LifeSciences: New Beginning
Integra LifeSciences specializes in neuro-related surgical devices and regenerative tissue technologies. The tissue reconstruction segment, featuring collagen-based products like Integra Skin and PriMatrix, is positioned as IART's primary future earnings driver. IART suffered significant earnings declines and a 75% share price drop due to FDA-related product recalls and operational lapses at its Boston facility.
IART vs. SONVY: Which Stock Is the Better Value Option?
Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Integra LifeSciences Holdings Corporation (IART) Hits Fresh High: Is There Still Room to Run?
Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference
PRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Bob Davis, executive vice president and president Tissue Reconstruction will present at the 2026 Truist Securities MedTech Conference on June 16, 2026 at 3:00pm ET.
Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference
PRINCETON, N. J. , June 15, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Bob Davis, executive vice president and president Tissue Reconstruction will present at the 2026 Truist Securities MedTech Conference on June 16, 2026 at 3:00pm ET.
Why Integra LifeSciences (IART) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Is Integra (IART) Up 15% Since Last Earnings Report?
Integra (IART) reported earnings 30 days ago. What's next for the stock?
IART vs. MASI: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and Masimo (MASI). But which of these two stocks presents investors with the better value opportunity right now?
Price Targets
Integra LifeSciences price target raised to $19 from $14 at Truist
$19.00
(was $19.75)
Truist Financial
BMO starts 'show-me story' Integra LifeSciences with a Market Perform
$19.00
(was $17.30)
BMO Capital
Integra LifeSciences upgraded to Buy from Hold at Argus
$25.00
(was $17.20)
Argus Research
Integra LifeSciences price target lowered to $12 from $13 at Truist
$12.00
(was $11.01)
Richard Newitter
·
Truist Financial
Integra LifeSciences price target raised to $15 from $13 at Truist
$15.00
(was $14.76)
Truist Financial
BTIG Upgrades Integra LifeSciences (IART) to Neutral
$20.00
(was $17.43)
Ryan Zimmerman
·
BTIG
Integra LifeSciences price target lowered to $26 from $32 at Truist
$26.00
(was $24.59)
Richard Newitter
·
Truist Financial
Citi Downgrades Integra LifeSciences (IART) to Sell
$23.00
(was $25.42)
Joanne Wuensch
·
Citigroup
Integra LifeSciences downgraded to Sell from Neutral at BTIG
$22.00
(was $25.42)
Ryan Zimmerman
·
BTIG
Integra LifeSciences price target raised to $32 from $25 at Truist
$32.00
(was $29.84)
Richard Newitter
·
Truist Financial
Integra LifeSciences (IART) PT Lowered to $25 at Truist Securities
$25.00
(was $23.14)
Richard Newitter
·
Truist Financial
Integra LifeSciences price target lowered to $40 from $49 at JMP Securities
$40.00
(was $23.14)
David Turkaly
·
JMP Securities
Wells Fargo Downgrades Integra LifeSciences (IART) to Equal Weight
$25.00
(was $23.14)
Vik Chopra
·
Wells Fargo
Piper Sandler keeps Neutral on Integra after results, favors Conmed and Tandem
$50.00
(was $46.85)
Matt O'Brien
·
Piper Sandler
Piper Sandler Cuts Price Target For Integra Lifesciences As It Divests Wound Care Portfolio
$55.00
(was $56.53)
FY22 EPS
·
Piper Sandler
Analysts Offer Insights on Healthcare Companies: Integra Lifesciences (NASDAQ: IART), Marinus (NASDAQ: MRNS) and ObsEva SA (NASDAQ: OBSV)
$86.00
(was $70.95)
Anthony Petrone
·
Jefferies
Integra LifeSciences price target raised to $74 from $68 at Wells Fargo
$74.00
(was $75.07)
Shagun Singh Chadha
·
RBC Capital
Integra LifeSciences (IART) PT Raised to $74 at Wells Fargo
$74.00
(was $75.07)
Larry Biegelsen
·
Wells Fargo